Silence Therapeutics PLC (LON:SLN) has given interim chief financial officer (CFO) Rob Quinn the job on a permanent basis.
Quinn has been the interim CFO since January 2019, having been the head of Financial Planning and Analysis at the company for the two years prior to getting the CFO gig.
READ Silence Therapeutics makes key new hire
“Rob's scientific and financial skills, alongside his commercial acumen make him an asset to the Silence team. During his time at the company he has continued to play an important role in building the business, with a keen appreciation for how we will grow in the future," said David Horn Solomon, the chief executive officer of the AIM-listed drugs developer.